Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ESTABLISHMENT LABS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ESTABLISHMENT LABS HOLDINGS's regulatory disclosures and financial reporting.
Establishment Labs Holdings Inc. filed a Form 8-K to share that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026. The company is furnishing, rather than filing, the investor presentation as Exhibit 99.1, meaning it is not subject to certain liability provisions that apply to filed information.
The report highlights that the materials may contain forward-looking statements and preliminary financial data prepared by management. The company notes that its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, or provided any assurance on this preliminary financial information, so it should not be relied on as a substitute for full GAAP financial statements.
Establishment Labs Holdings Inc. reported that it has issued a press release with preliminary, unaudited financial information for the quarter and full year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report.
The company emphasizes that these consolidated preliminary estimates are forward-looking statements, may differ materially from actual results, and are not a substitute for full financial statements prepared under U.S. GAAP. Its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, compiled, or performed any procedures on this preliminary information and does not provide any assurance on it.
Establishment Labs Holdings Inc. director Juan Jose Chacon Quiros reported new equity awards. On August 3, 2025, he received 10,285 common shares at a price of $0, increasing his directly held common shares to 224,433. These stock units were granted under the company’s 2018 Equity Incentive Plan and are tied to a post-employment agreement signed on that date and a consulting agreement effective June 1, 2025.
He was also granted a stock option for 14,906 common shares with an exercise price of $36.46, fully unexercised after the transaction. Both the stock units and the option vest in four equal annual installments starting on June 1, 2026, as long as he continues as a service provider. Separately, 1,078,264 common shares are held indirectly by Sariel Group Ltd, an entity where he has voting and dispositive power but for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Establishment Labs Holdings Inc. (ESTA) reported an insider transaction on a joint Form 4 by affiliates of JW Asset Management. On 11/10/2025, the group reported an open‑market sale of 11,000 common shares at a price of $67.07 per share. Following the transaction, the group reported 3,061,694 shares beneficially owned, held indirectly.
Footnotes state the sale comprised 8,205 shares by JW Partners, LP and 2,795 shares by JW Opportunities Fund, LLC, with standard disclaimers regarding indirect pecuniary interest.
Establishment Labs (ESTA) reported an insider transaction on a Form 4 by JW Asset Management, LLC and affiliated reporting persons. On 11/07/2025, the group sold 2,500 common shares in an open-market transaction at $65.09 per share (transaction code S). Following the sale, the reporting persons beneficially owned 3,072,694 shares, held indirectly.
Per the footnotes, the 2,500 shares reflect sales by two affiliated funds: 1,865 shares by JW Partners, LP and 635 shares by JW Opportunities Fund, LLC. The filing indicates the structure of control and advisory roles among JW Asset Management, LLC, JW GP, LLC, and Jason G. Wild, with beneficial ownership disclaimed except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings (ESTA) reported an insider transaction on a Form 4 involving multiple reporting persons affiliated with JW Asset Management. On 11/06/2025, the group sold 7,591 Common Shares at a price of $65 per share, coded “S” for sale. Following the transaction, 3,075,194 shares were reported as beneficially owned in aggregate with indirect ownership noted.
Footnotes state the sale comprised 5,662 shares by JW Partners, LP and 1,929 shares by JW Opportunities Fund, LLC. The filing lists JW Asset Management, LLC, JW Partners, LP, JW Opportunities Fund, LLC, JW GP, LLC, and Jason G. Wild as reporting persons, with customary beneficial ownership disclaimers. The form indicates it was filed by more than one reporting person.
Establishment Labs (ESTA) reported Q3 2025 results. Revenue reached $53.8 million, up from $40.2 million a year ago, with gross profit of $37.7 million. Operating loss narrowed to $4.0 million and net loss was $11.1 million, or $0.38 per share.
North America contributed $11.9 million in Q3 revenue versus $0.3 million in the prior year period. For the first nine months, revenue was $146.5 million and net loss was $48.4 million.
Cash and cash equivalents were $70.6 million at quarter-end. Year-to-date net cash used in operating activities was $50.7 million. Note payable, net, increased to $246.5 million from $219.6 million at year-end 2024, and shareholders’ equity declined to $16.4 million from $53.1 million. The company had 29,057,868 common shares outstanding as of November 6, 2025.
Establishment Labs Holdings Inc. (ESTA) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company made these results available through a press release attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not filed under the Exchange Act.
Establishment Labs Holdings Inc. entered into a fourth amendment to its credit agreement with Oaktree Fund Administration. The amendment makes the Tranche D term loans available as of the amendment’s effective date, removing the need to first achieve the revenue milestone originally required. It also raises the minimum liquidity the company and its guarantor subsidiaries must maintain from $25,000,000 to $30,000,000, effective September 28, 2025.
On the same day, the company fully drew the available Tranche D term loans, resulting in a new borrowing of $25,000,000 under the credit agreement. The amendment itself is filed as an exhibit to provide full details of the revised terms.
Edward J. Schutter, a director of Establishment Labs Holdings Inc. (ESTA), received 457 common shares as payment in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the Issuer’s 2018 Equity Incentive Plan and were valued based on the closing market price used to determine the share equivalent. After this issuance the reporting person beneficially owns 138,015 shares, held directly.